Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs Aflibercept in Diabetic Macular Edema (China extension of YOSEMITE/RHINE)
CTR20191228Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Started Jul 2019; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20191228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191228.